Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Are you a Dividend Trader
Learn how to make passive income from the best dividend stocks.
Health Technology » Pharmaceuticals Other
|VRX||Valeant Pharmaceuticals International, Inc.||-0.33%||16.73||14.1%||$230.62m|
|SHPG||Shire PLC Sponsored ADR||1.27%||133.45||0.4%||$145.98m|
|PRGO||Perrigo Co. Plc||-0.26%||84.24||6.6%||$98.68m|
|SAGE||SAGE Therapeutics, Inc.||-1.05%||172.22||9.7%||$84.76m|
|PTLA||Portola Pharmaceuticals, Inc.||-3.55%||34.83||7.8%||$63.14m|
|JAZZ||Jazz Pharmaceuticals Plc||3.63%||154.09||2.2%||$62.82m|
|UTHR||United Therapeutics Corporation||0.13%||111.14||14.5%||$59.96m|
|GWPH||GW Pharmaceuticals PLC Sponsored ADR||-0.46%||118.82||7.6%||$47.84m|
|ICPT||Intercept Pharmaceuticals, Inc.||0.43%||64.97||22.0%||$41.64m|
|ADMS||Adamas Pharmaceuticals, Inc.||2.46%||27.10||14.4%||$40.39m|
|ENDP||Endo International Plc||2.49%||7.01||8.9%||$39.16m|
SAGE Therapeutics, Inc. is a clinical stage biopharmaceutical company. The company engages in the development and commercialization of novel medicines to treat central nervous system disorders. Its product candidate includes SAGE-547, which is in clinical development for super-refractory status epileptics; SAGE-217; and SAGE-689, which are in IND-enabling toxicology and safety pharmacology testing. The company was founded by Steven Marc Paul and Douglas Covey in April 2010 and is headquartered in Cambridge, MA.